Clinical Trial Update: A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension [Phase 3]

View source ↗

Summary

This report covers the completion of a Phase III long-term study of TAK-536TCH in participants with essential hypertension. Results have been posted by Takeda.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• TAK-536TCH

Snippet

Sponsor: Takeda | Conditions: Essential Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2017-06-26